Hypertension remains the leading cause of cardiovascular disease and premature death
globally, affecting half of US adults. A high proportion of hypertensive patients exhibit …

Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …

Background Angiotensinogen is the sole precursor of angiotensin peptides and has a key
role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference …

Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat
hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if …

Blood pressure management involves antihypertensive therapies blocking the renin-
angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the …

Importance Angiotensinogen is the most upstream precursor of the renin–angiotensin–
aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an …

Small interfering RNAs (siRNAs) targeting hepatic angiotensinogen (Agt) may provide long-
lasting antihypertensive effects, but the optimal approach remains unclear. Here, we …

The prevalence of arterial hypertension is approximately 47% in the United States and 55%
in Europe. Multiple different medical therapies are used to treat hypertension including …

Angiotensinogen (AGT) is the precursor of active vasoconstrictive octapeptide angiotensin II
(Ang II) in the renin-angiotensin-aldosterone system. Blocking the AGT-converting enzymes …

Background: Angiotensinogen (AGT) is the sole precursor of all angiotensin peptides and
plays a key role in hypertension pathogenesis. We evaluated the effect of ALN-AGT01, a …